These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Incubators for innovators. Kirkpatrick L Nat Biotechnol; 2015 Feb; 33(2):129-32. PubMed ID: 25658271 [No Abstract] [Full Text] [Related]
25. Aftermarket Performance of Health Care and Biopharmaceutical IPOs: Evidence From ASEAN Countries. Komenkul K; Kiranand S Inquiry; 2017 Jan; 54():46958017727105. PubMed ID: 28853306 [TBL] [Abstract][Full Text] [Related]
27. Refinancing time. Investor-owned companies look for cheaper debt. Evans M Mod Healthc; 2010 Sep; 40(39):8-9. PubMed ID: 20931716 [No Abstract] [Full Text] [Related]
28. A new era of hope for the world's most neglected diseases. The PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790 [TBL] [Abstract][Full Text] [Related]
29. Is there transparency in the pricing of medicines in the South African private sector? Bangalee V; Suleman F S Afr Med J; 2018 Feb; 108(2):82-83. PubMed ID: 29429435 [TBL] [Abstract][Full Text] [Related]
30. Beyond the crunch. Nat Rev Drug Discov; 2009 Jan; 8(1):3. PubMed ID: 19123266 [No Abstract] [Full Text] [Related]
31. Current developments in private offerings. Mikula AV; Abraham S Health Care Law Mon; 2007 Oct; (10):2-6. PubMed ID: 18046934 [No Abstract] [Full Text] [Related]
33. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner. Wheeler C Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375 [No Abstract] [Full Text] [Related]
34. Public health. Capital gains. Black A; Hamilton L Health Serv J; 1997 Nov; 107(5578):26-7. PubMed ID: 10174010 [TBL] [Abstract][Full Text] [Related]
35. BioXell: an Italian biotech success story? Sheridan C Nat Biotechnol; 2006 Sep; 24(9):1045-6. PubMed ID: 16964198 [No Abstract] [Full Text] [Related]
36. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers. Feinberg MB; Gordon L Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589 [No Abstract] [Full Text] [Related]
37. A venture capital view of challenges, opportunities, and innovation in biomedical research. Ratcliffe LT Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935 [TBL] [Abstract][Full Text] [Related]
38. The promise of South African biotech. Akermann B; Kermani F Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404 [No Abstract] [Full Text] [Related]
39. The NIH budget and the future of biomedical research. Loscalzo J N Engl J Med; 2006 Apr; 354(16):1665-7. PubMed ID: 16625006 [No Abstract] [Full Text] [Related]